Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet? - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles Toxins Year : 2021

Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?

Abstract

Colibactin is a genotoxin produced primarily by Escherichia coli harboring the genomic pks island (pks+ E. coli). Pks+ E. coli cause host cell DNA damage, leading to chromosomal instability and gene mutations. The signature of colibactin-induced mutations has been described and found in human colorectal cancer (CRC) genomes. An inflamed intestinal environment drives the expansion of pks+ E. coli and promotes tumorigenesis. Mesalamine (i.e., 5-aminosalycilic acid), an effective anti-inflammatory drug, is an inhibitor of the bacterial polyphosphate kinase (PPK). This drug not only inhibits the production of intestinal inflammatory mediators and the proliferation of CRC cells, but also limits the abundance of E. coli in the gut microbiota and diminishes the production of colibactin. Here, we describe the link between intestinal inflammation and colorectal cancer induced by pks+ E. coli. We discuss the potential mechanisms of the pleiotropic role of mesalamine in treating both inflammatory bowel diseases and reducing the risk of CRC due to pks+ E. coli.
Fichier principal
Vignette du fichier
Fichaux-TOXIN-2021.pdf (1.33 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03594435 , version 1 (02-03-2022)

Licence

Attribution

Identifiers

Cite

Min Tang-Fichaux, Priscilla Branchu, Jean-Philippe Nougayrède, Eric Oswald. Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?. Toxins, 2021, 13 (12), 13 p. ⟨10.3390/toxins13120897⟩. ⟨hal-03594435⟩
39 View
51 Download

Altmetric

Share

Gmail Facebook X LinkedIn More